Litcius/Paper detail

COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review

Yosuke Goto, Koji Sakamoto, Jun Fukihara, Atsushi Suzuki, Norihito Omote, Akira Ando, Yuichiro Shindo, Naozumi Hashimoto

2022Frontiers in Medicine15 citationsDOIOpen Access PDF

Abstract

Because severe coronavirus disease 2019 (COVID-19) affects the respiratory system and develops into respiratory failure, patients with pre-existing chronic lung disorders, such as idiopathic pulmonary fibrosis (IPF), are thought to be at high risk of death. Patients with IPF often suffer from a lethal complication, acute exacerbation (AE), a significant part of which is assumed to be triggered by respiratory viral infection. However, whether mild to moderate COVID-19 can trigger AE in patients with IPF remains unknown. This is the case report of a 60-year-old man with a 4-year history of IPF who successfully recovered from moderate COVID-19 but subsequently developed more severe respiratory failure, which was considered to be a COVID-19-triggered acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). It is important to be aware of the risk of AE-IPF after COVID-19 and to properly manage this deadly complication of IPF. Recent literature reporting cases with chronic interstitial lung diseases which developed respiratory failure by complications with COVID-19 is also reviewed and discussed.

Topics & Concepts

Idiopathic pulmonary fibrosisExacerbationMedicineRespiratory failureInterstitial lung diseaseComplicationPulmonary fibrosisRespiratory systemIntensive care medicineDiffuse alveolar damageLungInternal medicineAcute respiratory distressInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisSarcoidosis and Beryllium Toxicity ResearchPneumocystis jirovecii pneumonia detection and treatment